681 USING NANOPORE SEQUENCING TO DIAGNOSE PROSTHETIC JOINT INFECTIONS
(2024)
Presentation / Conference
Wilkinson, H., Cool, P., Perry, J., Wright, K. T., McCarthy, H. S., & Hulme, C. H. (2024, April). 681 USING NANOPORE SEQUENCING TO DIAGNOSE PROSTHETIC JOINT INFECTIONS. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria
All Outputs (17)
437 CHARACTERISATION OF JUVENILE CARTILAGE TISSUES AND THEIR ISOLATED CHONDROCYTES FOR ALLOGENEIC CHONDROCYTE THERAPY (2024)
Presentation / Conference
Hulme, C. H., Perry, J., McCarthy, H. S., Freeman, R., Kiely, N., & Wright, K. T. (2024, April). 437 CHARACTERISATION OF JUVENILE CARTILAGE TISSUES AND THEIR ISOLATED CHONDROCYTES FOR ALLOGENEIC CHONDROCYTE THERAPY. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria
361 ADDITION OF THROMBIN TO BONE MARROW CONCENTRATE DURING THE TREATMENT OF ANKLE CARTILAGE DEFECTS SIGNIFICANTLY INCREASES THE CONCENTRATION OF INTERLEUKIN-1 RECEPTOR ALPHA AND PLATELET-DERIVED GROWTH FACTOR BB (2024)
Presentation / Conference
Lan, T., Wright, K. T., Makwana, N., Bing, A., McCarthy, H. S., & Hulme, C. H. (2024, April). 361 ADDITION OF THROMBIN TO BONE MARROW CONCENTRATE DURING THE TREATMENT OF ANKLE CARTILAGE DEFECTS SIGNIFICANTLY INCREASES THE CONCENTRATION OF INTERLEUKIN-1 RECEPTOR ALPHA AND PLATELET-DERIVED GROWTH FACTOR BB. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria
169 AGGRECANASE-1 ACTIVITY IN THE SYNOVIAL FLUID OF CARTILAGE INJURY CELL THERAPY TRIAL COHORT PREDICTS OUTCOME 1-YEAR POST TREATMENT. (2024)
Presentation / Conference
Rix, L., Hulme, C. H., Kuiper, J. H., Mennan, C., Gallacher, P., Jermin, P., & Wright, K. T. (2024, January). 169 AGGRECANASE-1 ACTIVITY IN THE SYNOVIAL FLUID OF CARTILAGE INJURY CELL THERAPY TRIAL COHORT PREDICTS OUTCOME 1-YEAR POST TREATMENT. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria
Proteomic Profiling of Different Clinical Responses to Surgically Sustained and Acute Traumatic Cartilage Injuries (2023)
Presentation / Conference
Hulme, C., McDonald, J., Williams, A., Vincent, T. L., Watt, F. E., & Wright, K. (2023, September). Proteomic Profiling of Different Clinical Responses to Surgically Sustained and Acute Traumatic Cartilage Injuries. Paper presented at 17th ICRS World Congress 2023, Stiges, Barcelona, Spain
Total Nucleated Cell Count in Bone Marrow Aspirate Concentrate Does Not Predict the Proportion of Mesenchymal Stem Cells (2023)
Presentation / Conference
Wright, K., Makwana, N., Bing, A., Hulme, C., & McCarthy, H. (2023, September). Total Nucleated Cell Count in Bone Marrow Aspirate Concentrate Does Not Predict the Proportion of Mesenchymal Stem Cells. Paper presented at 17th ICRS World Congress 2023, Stiges, Barcelona, Spain
Analysis of Synovial Fluid Proteomes After Treating an Ovine Osteoarthritic Model with Human Umbilical Cord Mesenchymal Stem Cells (2023)
Presentation / Conference
McDonald, J., Wright, K., Mennan, C., Peffers, M., Perry, J., Roberts, S., …Hulme, C. (2023, September). Analysis of Synovial Fluid Proteomes After Treating an Ovine Osteoarthritic Model with Human Umbilical Cord Mesenchymal Stem Cells. Presented at International Cartilage and Joint Preservation Society World Congress 2023, Melia Hotel Sitges, Sitges/ Barcelona
Umbilical Cord MSC Treated Osteoarthritic Sheep Display Reduced Radiographic Changes: Proteomic Biomarker Profiling of Synovial Fluids Implicate an Immunomodulatory Mechanism (2023)
Presentation / Conference
Perry, J., Mennan, C., Cool, P., Mccarthy, H., Newell, K., Hulme, C., …Roberts, S. (2023, March). Umbilical Cord MSC Treated Osteoarthritic Sheep Display Reduced Radiographic Changes: Proteomic Biomarker Profiling of Synovial Fluids Implicate an Immunomodulatory Mechanism. Presented at TERMIS 2023 – European Chapter, Manchester Central Conference Centre Manchester, UK
Assessing allogeneic chondroprogenitor manufacture in xeno-free and serum-free media (2022)
Presentation / Conference
Hulme, C., Bailey, S., Hopkins, T., Mccarthy, H., Snow, M., & Wright, K. (2022, April). Assessing allogeneic chondroprogenitor manufacture in xeno-free and serum-free media. Presented at International Cartilage Regeneration and Joint Preservation Society (ICRS) World Congress 2022, Berlin, Germany
Altered Acute Phase Response (APR) signalling following cartilage harvest can be identified in the plasma of ‘non-Responder’ Patients to Autologous Chondrocyte Implantation (2021)
Presentation / Conference
Hulme. (2021, September). Altered Acute Phase Response (APR) signalling following cartilage harvest can be identified in the plasma of ‘non-Responder’ Patients to Autologous Chondrocyte Implantation. Presented at British Orthopaedic Research Society (BORS) 2021, Virtual (Hosted by Imperial College London)
Matrix mettaloproteinase-3 (MMP-3) and tissue inhibitors of metalloproteinases-1 (TIMP-1): potential biomarkers to predict the outcome of Autologous Chondrocyte Implantation (2019)
Presentation / Conference
Hulme, C., Roberts, S., Gallacher, P., Jermin, P., Richardson, J., & Wright, K. (2019, October). Matrix mettaloproteinase-3 (MMP-3) and tissue inhibitors of metalloproteinases-1 (TIMP-1): potential biomarkers to predict the outcome of Autologous Chondrocyte Implantation. Paper presented at International Joint and Cartilage Preservation Society (ICRS) 2019, Vancouver, Canada
Up-scale manufacture of chondrocytes in the development of allogeneic cartilage therapies (2018)
Presentation / Conference
Hulme, C., & Mennan, C. (2018, December). Up-scale manufacture of chondrocytes in the development of allogeneic cartilage therapies
Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs) (2018)
Presentation / Conference
Hulme, C., Wilson, E., Fuller, H., Roberts, S., & Wright, K. (2018, December). Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs). Paper presented at Matrix Biology Europe 2018
Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs) (2018)
Presentation / Conference
Hulme, C., Wilson, E., Fuller, H., Roberts, S., Richardson, J., Gallacher, P., …Wright, K. (2018, July). Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs). Poster presented at Matrix Biology Europe – July 2018 Meeting Celebrating 50 years of Federation of European Connective Tissue Societies Meetings, Manchester, United KingdomIntroduction: Autologous chondrocyte implantation (ACI) is a cell therapy used to treat cartilage defects and early osteoarthritis. During initial surgery (Stage I), healthy cartilage is harvested from the joint. Chondrocytes are isolated and culture... Read More about Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs).
IS ORTHOPAEDICS LEADING THE WAY IN GETTING CELL THERAPY TO THE CLINIC?
Presentation / Conference
Mennan, Hulme, & Wright, K. IS ORTHOPAEDICS LEADING THE WAY IN GETTING CELL THERAPY TO THE CLINIC?. Presented at Termis EU Chapter 2020
The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies
Presentation / Conference
Mennan, C., Hulme, C., Garcia, J., Perry, J., Roberts, S., Norris, K., …Wright, K. T. The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies. Poster presented at TERMIS-EU 2020 Chapter MeetingINTRODUCTION: Up-scaled allogeneic cellular products for cartilage therapies, along with identification of novel young donors of healthy chondrocytes, are needed to improve the cost effectiveness and wide-spread use of chondrocyte therapy.
METHODS... Read More about The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies.
Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?
Presentation / Conference
Hulme, C., & Wright, K. Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?. Presented at International Cartilage Regeneration and Joint Preservation Society (ICRS) World Congress 2022Purpose
Development of novel allogeneic chondrocyte therapies are needed to provide a more widespread, cost-effective cartilage treatment option. Here we investigate the potential of juvenile cartilage sources for allogeneic chondrocyte manufactur... Read More about Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?.